Measurement of the expression of ARV7 on circulating tumor cells (CTCs) obtained from a blood test1 has previously been studied and found to correlate with patient response to novel hormone therapy (NHT) drugs (Enzalutamide and Abiraterone).
| GUILDFORD, SURREY -- (Marketwired) -- Jan 08, 2018 -- ( For immediate release 8 January 2018 ANGLE plc (“the Company”) RESEARCH DEMONSTRATES USE OF PARSORTIX™ LIQUID BIOPSY TO DETECT ARV7 IN PROSTATE CANCER AS A TREATMENT SELECTION BIOMARKER Parsortix-based ARV7 test may provide a wider understanding of ARV7 than other techniques with the potential for improved patient outcomes Independent research estimates that an ARV7 test could save, on average, at least $5,000 per patient tested Angle ( The research has been published in Clinical Chemistry. A copy of the publication is available on ANGLE’s website here https://angleplc.com/library/publications/. Measurement of the expression of ARV7 on circulating tumor cells (CTCs) obtained from a blood test1 has previously been studied and found to correlate with patient response to novel hormone therapy (NHT) drugs (Enzalutamide and Abiraterone). Where ARV7 is positively expressed, patients are unlikely to respond to NHT and benefit from moving directly to taxane-based chemotherapies. Where ARV7 is not expressed, patients do better when receiving NHT first and only moving to chemotherapy subsequently. Researchers believe that an ARV7 test utilising the Parsortix system for CTC enrichment could provide key advantages over other approaches. These include:
Cancer is a heterogeneous disease and this increased level of resolution in analysis of ARV7 could add important understanding of how best to treat the patient. Independent research has also suggested that, in addition to improved patient outcomes, avoiding the use of expensive NHT drugs when the patient is ARV7 positive has the potential to reduce the cost for healthcare resources. A cost-benefit analysis published in the Journal of Clinical Oncology estimated that an ARV7 test costing $1,000 per patient would result in cost savings averaging $5,000 per patient, with cost saving of at least $20,000 per patient with a positive ARV7 result. Dr Amin El-Heliebi, Principal Investigator, Medical University of Graz, commented: ANGLE’s Founder and Chief Executive, Andrew Newland, added: 1. ARV7 analysis requires the investigation of CTCs as undertaken by the Parsortix system and cannot be undertaken using the alternative ctDNA approach utilised by other companies. For further information ANGLE:
ANGLE plc +44 (0) 1483 343434 Andrew Newland, Chief Executive Ian Griffiths, Finance Director finnCap Ltd (NOMAD and Joint Broker) +44 (0)20 7220 0500 Corporate Finance - Adrian Hargrave, Simon Hicks, Kate Bannatyne Corporate Broking - Alice Lane, Nikita Jain WG Partners (Joint Broker) +44 (0) 203 705 9330 Nigel Barnes, Nigel Birks, Andrew Craig, Chris Lee FTI Consulting Simon Conway, Mo Noonan, Stephanie Cuthbert +44 (0) 203 727 1000 Kimberly Ha (US) +1 212 850 5612 For Frequently Used Terms, please see the Company’s website on http://www.angleplc.com/the-parsortix-system/glossary/ This announcement contains inside information. Notes for editors About ANGLE plc www.angleplc.com ANGLE’s cell separation technology is called the Parsortix™ system and it enables a liquid biopsy (simple blood test) to be used to provide the cells of interest. Parsortix is the subject of granted patents in Europe, the United States, Canada, India, China, Japan and Australia and three extensive families of patents are being progressed worldwide. The system is based on a microfluidic device that captures live cells based on a combination of their size and compressibility. The Parsortix system has a CE Mark for Europe and FDA clearance is in process for the United States. ANGLE’s analysis technology for proteins and nucleic acids of all types is based on a patented flow through array technology. It provides for highly multiplexed, rapid and sensitive capture of targets from a wide variety of sample types. A proprietary chemistry allows for the capture and amplification of over 100 biomarkers simultaneously in a single reaction. These technologies can be combined to provide fully automated, sample to answer results in both centralized laboratory and point of use cartridge formats. It is ideal for measuring gene expression and other markers directly from Parsortix harvests. ANGLE has established formal collaborations with world-class cancer centres. These Key Opinion Leaders are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. Details are available here http://www.angleplc.com/the-company/collaborators/ The analysis of the cells that can be harvested from patient blood with ANGLE’s Parsortix system has the potential to help deliver personalised cancer care offering profound improvements in clinical and health economic outcomes in the treatment and diagnosis of various forms of cancer. The global increase in cancer to a 1 in 3 lifetime incidence is set to drive a multi-billion dollar clinical market. The Parsortix system is designed to be compatible with existing major medtech analytical platforms and to act as a companion diagnostic for major pharma in helping to identify patients that will benefit from a particular drug and then monitoring the drug’s effectiveness. As well as cancer, the Parsortix technology has the potential for deployment with several other important cell types in the future. ANGLE biomarker analysis platforms are adaptable to measure protein and nucleic acid biomarkers across the full spectrum of disease applications. ANGLE stock trades on the AIM market of the London Stock Exchange under the ticker symbol AGL and in New York on the OTC-QX under the ticker symbol ANPCY. For further information please visit: www.angleplc.com
Contacts: RNS Customer Services 0044-207797-4400 rns@londonstockexchange.com http://www.rns.com
|
